HIGHLIGHTS
- who: Adam Hermawan from the Laboratory of Macromolecular Engineering, Department of Pharmaceutical Yogyakarta, Indonesia have published the research: Bioinformatics analysis reveals the potential target of rosiglitazone as an antiangiogenic agent for breast cancer therapy, in the Journal: (JOURNAL)
- what: This study explored the potential targets of RGZ as antiangiogenic agents in highlighted FABP4 ADIPOQ PPARG PPARGC1A CD36 CREBBP as potential targets of RGZ. The authors propose a mechanism by which RGZ inhibits angiogenesis by targeting TR (Fig 8). The results of this study were obtained using a bioinformatics approach. In this study, the potential of . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.